Subject:
- Active Substance: Secukinumab
- Name: Cosentyx®
- Therapeutic area: Hidradenitis suppurativa (HS)
- Pharmaceutical company: Novartis Pharma GmbH
Time table:
- Start: 15.06.2023
- Publication of assessment: 15.09.2023
- End of public hearing: 06.10.2023
- Final decision by G-BA: beginning of December 2023
Comparative therapy:
- Adalimumab